SUMMARY In a screening service for breast cancer the results of routine repeat tests of women will contribute more than the results of their initial tests. A comparison of first and subsequent screens in a group of high risk women suggests that the sensitivity of screening declines between first and subsequent visits, whereas its specificity improves. Despite improved specificity, the ratio of benign biopsies to cancer was worse at repeated screening (21 to 1) than at first screening (6 to 1). This was because between first and subsequent screens the yield of cancers fell to a greater extent than the yield of benign disease. The patients with breast cancer diagnosed during this study were remarkable for their good prognosis, 92% being still alive and 86% free from recurrence at their last follow up, the follow up intervals ranging from four to eight years.
In the West London feasibility study of different screening methods for breast cancer a self selected group of women aged 40 and over were screened on four successive occasions. Information was collected on the sensitivity, specificity, and cost of screening by clinical examination alone, mammography alone, and by these two modalities combined. Previous reports have described the results of each screening modality at the initial visit1" and of the four repeated screens grouped together.4 The present paper compares the yield of both breast cancer and benign breast disease at the first screen with that at subsequent screens and discusses how the validity of the tests alters between first and subsequent screens. Follow up information on the survival and disease free interval of all patients with cancer diagnosed during the course of this study is also presented. The prevalence of benign disease was nearly 130 per 1000 at first screening and the yield thereafter fell to around 45 per 1000. Not all of this benign disease found at repeated screening was new; some was persistence of a chronic condition. Sixty four women were referred twice with a benign abnormality, 12 were referred three times, and one was referred after all four screens. Twenty three women had benign biopsies after two different screening visits.
SENSITIVITY
It is a common convention in cancer screening to regard cancers presenting symptomatically in the interval between one screen and the next as false negative results to the previous screen. Sensitivity is defined by the number of cancers detected at a screen expressed as a proportion of those detected at the screen plus those that present symptomatically before the next screen is due. Table 4 shows that were diagnosed at a detected at subseq between screens whether they tend than those detecte( Repeated screening for breast cancer monotonous nature of the task or by a different case mix of preclinical lesions available for detection. In a previously unscreened population it can be expected that some preclinical cases will be of relatively long duration and hence by implication may be larger and more easily detectable than the new cases available for detection at subsequent screens, whose duration can be no longer than the screening interval. The denominator used for estimating sensitivity includes all cancers detected at screening and all interval cases presenting before the next screen. Even if the number and behaviour of interval cases is the same after the first and subsequent screens they form a smaller proportion of the total number of cancers when considering the first screen with its high yield than in subsequent screens. Hence, sensitivity estimates based on initial screening may give an overoptimistic view of the proportion of cancers that can be detected by screening in continuous service.
The low specificity in this survey was partly caused by the self selection of participants with symptoms and partly by the study design in which referral for surgical opinion was based on the independent verdict of any of the screeners without consultation between them. No other studies that we are aware of have reported the specificity of subsequent screens. It is of interest that, although specificity improved substantially from the initial value, the ratio of benign to malignant biopsies became worse, because the yield of benign abnormalities did not fall to the same extent as that of cancers. If this finding is borne out by population based studies now in progress7 it will have implications both for the way in which women are told of the need for biopsy, and for calculating the total cost of the screening programme.
The patients found to have breast cancer in this study are remarkable for their very good prognosis. It is invalid, however, to make a comparison between cancers detected by screening with others, because of the biasses of lead time, length bias, and patient selection.8 One might expect that the interval cases 57 would represent faster growing cancers with a poor prognosis, but this applied only to one of the five, the remaining four being alive with no recurrence at follow up five to seven years after diagnosis. The fact that these four were at an early stage at the time of diagnosis may indicate that this group of women had a heightened awareness of breast abnormalities and knew of the need to take action. The good prognosis for screening detected cancers is certainly not proof of the value of screening but is consistent with the hope that it may be effective in saving lives.
We 
